Onyx Biotec P/B Ratio
Current P/B Ratio
1.34
Moderate Valuation
Moderate - Reasonably valued relative to book value
Onyx Biotec (ONYX) P/B ratio is 1.34 (Moderate), book value per share ₹30.56 vs Healthcare average P/B of -0.01 — Moderate - Reasonably valued relative to book value. View Onyx Biotec 52-week for the annual high/low range and current price position.
Current Valuation Metrics
P/B Ratio
1.34
Current Price
₹
Book Value/Share
₹30.56
Exchange
None
Book Value Breakdown (2026)
Balance Sheet Components
Total Equity
₹55 Cr
Share Capital
₹18 Cr
Reserves & Surplus
₹37 Cr
Outstanding Shares
18,000,000
Book Value per Share
₹30.56
Valuation Signal
Signal
Fairly Valued
Sector Context
Sector Average
-0.01
Sector Median
0.62
Sector Rank
#11 of 50
Sector Percentile
22.0%
ONYX P/B Ratio — Valuation Insights & Book Value Analysis
Onyx Biotec price-to-book ratio interpretation, valuation status and historical context — current P/B 1.34 (Moderate). Review ONYX P/E ratio to evaluate earnings-based valuation against sector peers.
- Trading at premium to sector average PB of -0.01
ONYX vs Healthcare Peers — P/B Ratio Comparison
Onyx Biotec P/B 1.34 vs Healthcare average -0.01, median 0.62 — range -6.55–1.14.
Sector Average
-0.01
Sector Median
0.62
Lowest P/B
-6.55
Highest P/B
1.14
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Parmax Pharma | PARMAX | -6.55 | ₹46 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.14 | ₹70 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.74 | ₹118 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.16 | ₹43 | Low |
| Triochem Products | TRIPR | 0.04 | ₹0 | Low |